title: Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment.
abstract: Repeated asparaginase treatment has been associated with hypersensitivity reactions against the bacterial macromolecule in a considerable number of patients. Immunological reactions may range from anaphylaxis without impairment of serum asparaginase activity to a very fast decline in enzyme activity without any clinical symptoms. Previous investigations on a limited number of patients have shown high interindividual variability of asparaginase activity time courses and hypersensitivity reactions in about 30% of patients during reinduction treatment. Therefore, monitoring of reinduction treatment was performed prospectively in 76 children with newly diagnosed acute lymphoblastic leukaemia (ALL). According to the ALL-Berlin-Frankfurt-Münster (BFM) 95 protocol, 10 000 U/m2 body surface area of native Escherichia coli asparaginase (Asparaginase medac) was given on d 8, 11, 15 and 18. In 45/76 children, trough and peak activities were determined with every dose, and also on d 4 and d 11 after the last administration. Data on asparaginase activity were not available from the remaining 31 patients, but information with regard to hypersensitivity reactions only was given. Eighteen out of 76 patients (24%) suffered a clinical hypersensitivity reaction; however, no silent inactivation was observed. Activity in the therapeutic range of greater than 100 U/l for at least 14 d was determined in 43 of the 45 patients who were analysed for enzyme activity.
authors.affiliation: Department of Paediatric Haematology/Oncology, University of Münster, Germany. hmuller@uni-muenster.de
authors.forename: H J
authors.initials: HJ
authors.lastname: Müller
authors.forename: R
authors.initials: R
authors.lastname: Beier
authors.forename: L
authors.initials: L
authors.lastname: Löning
authors.forename: R
authors.initials: R
authors.lastname: Blütters-Sawatzki
authors.forename: W
authors.initials: W
authors.lastname: Dörffel
authors.forename: E
authors.initials: E
authors.lastname: Maass
authors.forename: S
authors.initials: S
authors.lastname: Müller-Weihrich
authors.forename: H G
authors.initials: HG
authors.lastname: Scheel-Walter
authors.forename: F
authors.initials: F
authors.lastname: Scherer
authors.forename: K
authors.initials: K
authors.lastname: Stahnke
authors.forename: M
authors.initials: M
authors.lastname: Schrappe
authors.forename: A
authors.initials: A
authors.lastname: Horn
authors.forename: K
authors.initials: K
authors.lastname: Lümkemann
authors.forename: J
authors.initials: J
authors.lastname: Boos
mesh_terms: D000293:Adolescent; D000707:Anaphylaxis / Q000209:etiology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001215:Asparaginase / Q000009:adverse effects* / Q000097:blood / Q000493:pharmacokinetics; D002648:Child; D002675:Child, Preschool; D004342:Drug Hypersensitivity / Q000209:etiology*; D016903:Drug Monitoring; D004789:Enzyme Activation; D004926:Escherichia coli / Q000201:enzymology*; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000201:enzymology / Q000276:immunology*; D011446:Prospective Studies
chemical_list: D001215:Asparaginase